COMMUNIQUÉS West-GlobeNewswire

Mark Holland Joins Canadian Men’s Health Foundation As One Of Its Newest Board Members
11/09/2026
VANCOUVER, British Columbia, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Former Health Minister, Mark Holland, joins a leading men’s health organization, as one of its newest board members. Mark Holland joins the Canadian Men’s [...]
GENFIT va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris
11/09/2026
Lille (France), Cambridge (Massachusetts, États-Unis), le 11 septembre 2026 – GENFIT (Euronext: GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie [...]
GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
11/09/2026
Lille (France), Cambridge (Massachusetts, United States), September 11, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver [...]
Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470
11/09/2026
Communiqué de presse Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470 L’acceptation du dossier de NCX 470 marque le début du processus d’examen réglementaire Une décision réglementaire est attendue [...]
Nicox Announces NCX 470 NDA in China Accepted for Review
11/09/2026
Press Release Nicox Announces NCX 470 NDA in China Accepted for Review Acceptance of the NCX 470 dossier initiates the review process Regulatory decision expected within 12-18 months from the August submission Q&A [...]
Persica Pharmaceuticals publishes new analysis of assay sensitivity in disc microbiology studies, reinforcing the potential for PP353 in vertebrogenic Lumbar Back Pain
11/09/2026
Publication strengthens the scientific rationale for PP353 as a precisely targeted, non-opioid treatment for patients with vertebrogenic Lumbar Back Pain Manuscript submitted to the European Spine Journal and is [...]
Resolution Therapeutics completes enrollment in Phase I/II EMERALD clinical trial evaluating RTX001 in end-stage liver disease
11/09/2026
15 patients dosed with RTX001, an engineered Regenerative Macrophage Therapy designed to address inflammation and fibrosis EMERALD is evaluating safety and efficacy of RTX001 in patients with end-stage liver disease and [...]
Avance Clinical Wins ANZCham's Australia-Taiwan Business Excellence Award in Taiwan
11/09/2026
TAIPEI, Taiwan, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Avance Clinical Taiwan has won the Australia-Taiwan Business Excellence Award at the 2026 Australia New Zealand Chamber of Commerce in Taiwan (ANZCham Taiwan) Business [...]
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s [...]
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
10/09/2026
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic [...]
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
10/09/2026
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) -- XORTX [...]
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
10/09/2026
Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methods Dosing of additional patients with the new process at LyFE continues with [...]
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
10/09/2026
HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug [...]
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
10/09/2026
GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive [...]
COSCIENS ACQUIRES NUALTIS CORP.
10/09/2026
TORONTO, ONTARIO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) is pleased to announce the acquisition of Nualtis Corp. (“ Nualtis ”), a Montreal [...]
Flyte Partners With Christian Cowan for New York Fashion Week, Expanding Its Presence Across Global Luxury Brands
10/09/2026
Strategic Partnership Positions Flyte at the Intersection of Private Aviation, Fashion, and Entertainment Collaboration Introduces Flyte to a High-Value Audience of Celebrities, Executives, Creators and Cultural [...]
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
10/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today [...]
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
10/09/2026
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock [...]
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
10/09/2026
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, [...]

Pages